Equillium, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EQ research report →
Companyequilliumbio.com
Equillium, Inc. , a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis.
- CEO
- Bruce D. Steel
- IPO
- 2018
- Employees
- 35
- HQ
- La Jolla, CA, US
Price Chart
Valuation
- Market Cap
- $73.17M
- P/E
- -10.41
- P/S
- 0.00
- P/B
- 3.33
- EV/EBITDA
- -0.62
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -61.43%
- ROIC
- -33.86%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-22,398,000 · -177.65%
- EPS
- $-0.39 · -69.57%
- Op Income
- $-23,634,000
- FCF YoY
- -19.27%
Performance & Tape
- 52W High
- $2.70
- 52W Low
- $0.27
- 50D MA
- $2.06
- 200D MA
- $1.54
- Beta
- 1.67
- Avg Volume
- 430.35K
Get TickerSpark's AI analysis on EQ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 13, 26 | Zedelmayer Christine | other | 120,312 |
| Mar 13, 26 | Zedelmayer Christine | sell | 120,312 |
| Mar 13, 26 | Zedelmayer Christine | other | 120,312 |
| Feb 19, 26 | Zedelmayer Christine | other | 109,375 |
| Feb 19, 26 | Zedelmayer Christine | other | 76,562 |
| Feb 19, 26 | Zedelmayer Christine | sell | 109,375 |
| Feb 19, 26 | Zedelmayer Christine | sell | 76,562 |
| Mar 9, 26 | Zedelmayer Christine | other | 75,000 |
| Mar 9, 26 | Zedelmayer Christine | other | 41,666 |
| Mar 9, 26 | Zedelmayer Christine | other | 35,695 |
Our EQ Coverage
We haven't published any research on EQ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EQ Report →